ClinicalTrials.gg
RecruitingNCT07464106TriRenGeUpdated Mar 11, 2026

Evaluation of the Impact of Interventional Treatments for Symptomatic, Severe Tricuspid Valve Insufficiency on Renal Integrity and Function, as Well as on Physical Function and Activity in Older Adults.

An observational study in Tricuspid Regurgitation, Tricuspid Valve Insufficiency and Cardio-Renal Syndrome, sponsored by Robert Bosch Medical Center. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Robert Bosch Medical Center · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Tricuspid Valve Insufficiency with a site in Germany — 24 open to participants now, 31 under way, none of them phase 3. Tricuspid Valve Insufficiency · Germany.

Planned enrollment
24th of 26
100 · median 506
Started
2025
with 2 others
Observational
26 of 51
17 open now
Primary completion
2026-12
later than 13 of 30 live
Registered
46th of 51
by date

Among the 51 studies in Tricuspid Valve Insufficiency with a site in Germany, this one is the 24th largest by planned enrollment of the 26 observational ones that give a count, is one of 3 that started in 2025, is one of 26 observational ones, reaches primary completion later than 13 of the 30 other live ones, and was the 46th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

24 of the 51 studies in Tricuspid Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Tricuspid Valve Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

The hypothesis is that renal function will improve following tricuspid valve intervention. A reduction in renal biomarkers is also expected. Furthermore, based on previous assessments, it is anticipated that there will be an improvement in volume status (reduced edema), symptom burden, and physical capacity in patients. Additionally, the study will assess the impact of the intervention on functional parameters such as motor capacity, physical activity, performance of activities of daily living, and ultimately, participation and quality of life.

03

Conditions studied

  • Tricuspid Regurgitation
  • Tricuspid Valve Insufficiency
  • Cardio-Renal Syndrome
  • Frailty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population includes adult patients with severe symptomatic tricuspid valve insufficiency who are referred for TriClip/TricValve screening and are aged 18 years or older. Participants must be able to provide informed consent and have the capacity to walk short distances with the aid of mobility devices.

Exclusion criteria include dialysis-dependent or terminal kidney disease, inability to comply with study-related assessments (e.g., due to dementia or cognitive decline), severe anemia (Hb \<7 g/dl), and the need for a tricuspid valve intervention with palliative intent, with a likely imminent death. Additionally, patients who are unable or unwilling to provide informed consent will be excluded from the study.

This population represents individuals who are eligible for the intervention, while the exclusions ensure that participants can meaningfully engage in the study assessments and outcomes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe symptomatic tricuspid valve insufficiency and referral for TriClip/TricValve screening
  • Completed 18th year of life
  • Ability to consent
  • Able to walk short distances with aids

Exclusion criteria

Exclusion Criteria:

  • Dialysis-dependent/terminal kidney disease
  • Inability to comply with study-associated assessments (e.g., existing dementia)
  • Severe anemia ( \<7 g/dl)
  • Tricuspid valve intervention with palliative intent and likely imminent death
  • Lack of consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • TEER-Group

    Tricuspid regurgitation group prior to intervention and after intervention

    Procedure: Transcatheter edge-to-edge repair (TEER)

Interventions

  • ProcedureTranscatheter edge-to-edge repair (TEER)

    Routine intervention, observational

06

What researchers measure

Primary outcomes

  1. Change in estimated glomerular filtration rate (eGFR) slope

    Annual change in estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation based on serial serum creatinine measurements (ml/min/1.73m² per year)

    Time frame: Baseline, 6 months, 12 months, and 24 months

  2. Incidence of acute kidney injury (AKI)

    Occurrence of acute kidney injury defined according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria based on changes in serum creatinine.

    Time frame: Baseline, 6 months, 12 months, and 24 months

  3. Physical activity assessed using the activPAL4 micro activity monitor

    Physical activity measured over a 7-day monitoring period using the activPAL4 micro activity monitor (PAL Technologies, Glasgow, UK)

    Time frame: Baseline, 6 months, 12 months, and 24 months

  4. Change in functional exercise capacity assessed with the 6-minute walk test (6MWT)

    Change in functional exercise capacity measured by the 6-minute walk test (6MWT)

    Time frame: Baseline, 6 months, 12 months, and 24 months

Secondary outcomes

  1. Change in kidney venous stasis index (KVSI)

    Change in kidney venous stasis index (KVSI) measured by duplex ultrasound

    Time frame: Baseline, 6 months, 12 months, and 24 months

  2. Change in body mass index (BMI)

    Change in body mass index calculated as body weight in kilograms divided by height in meters squared (kg/m²).

    Time frame: Baseline, 6 months, 12 months, and 24 months

  3. Hospitalizations due to heart failure

    Number of hospitalizations due to worsening heart failure during the study period.

    Time frame: Baseline, 6 months, 12 months, and 24 months

  4. Change in disease-specific quality of life assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ-12)

    Change in disease-specific quality of life measured using the Kansas City Cardiomyopathy Questionnaire short form (KCCQ-12)

    Time frame: Baseline, 6 months, 12 months, and 24 months

  5. Change in independence in activities of daily living assessed with the Katz Index

    Change in independence in activities of daily living measured using the Katz Index.

    Time frame: Baseline, 6 months, 12 months, and 24 months

  6. Change in frailty assessed using the Clinical Frailty Scale (CFS)

    Change in frailty status measured using the Clinical Frailty Scale (CFS)

    Time frame: Baseline, 6 months, 12 months, and 24 months

  7. Change in hand grip strength measured using a Jamar dynamometer

    Change in muscle strength assessed by hand grip strength using a manual dynamometer (Jamar).

    Time frame: Baseline, 6 months, 12 months, and 24 months

  8. Change in functional mobility assessed with the Timed Up and Go Test (TUG)

    Change in functional mobility measured using the Timed Up and Go Test (TUG), assessing the time required to stand up, walk three meters, turn, return, and sit down.

    Time frame: Baseline, 6 months, 12 months, and 24 months

  9. Change in urinary albumin-to-creatinine ratio (UACR)

    Change in albuminuria measured as urinary albumin-to-creatinine ratio (UACR) in spot urine samples (mg/gCreatinine)

    Time frame: Baseline, 6 months, 12 months, and 24 months

  10. Prevalence of chronic kidney disease (CKD)

    Presence of chronic kidney disease defined according to KDIGO criteria based on estimated glomerular filtration rate (eGFR) and markers of kidney damage.

    Time frame: Baseline, 6 months, 12 months, and 24 months

  11. Incidence of dialysis initiation

    Initiation of chronic renal replacement therapy (hemodialysis or peritoneal dialysis)

    Time frame: Baseline, 6 months, 12 months, and 24 months

  12. All-cause mortality

    Death from any cause during the study period

    Time frame: Baseline, 6 months, 12 months, and 24 months

  13. Change in cognitive function assessed with the Blessed Orientation-Memory-Concentration Test (BOMCT)

    Change in cognitive function measured using the Blessed Orientation-Memory-Concentration Test (BOMCT)

    Time frame: Baseline, 6 months, 12 months, and 24 months

  14. Change in emotional well-being assessed with the "Allgemeine Depressionsskala" short form (ADS-K)

    Change in depressive symptoms assessed using the short version of the general depression scale (ADS-K)

    Time frame: Baseline, 6 months, 12 months, and 24 months

  15. Change in body composition measured by bioelectrical impedance analysis (BIA)

    Change in body composition assessed by bioelectrical impedance analysis using the AKERN BIA 101 device.

    Time frame: Baseline, 6 months, 12 months, and 24 months

  16. Change in Venous Excess Ultrasound (VExUS) Score

    Change in VExUS Score (bedside ultrasound-based approach with a more comprehensive assessment of venous congestion) measured by duplex ultrasound

    Time frame: Baseline, 6 months, 12 months, and 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 47 observational studies under Tricuspid Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 106. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Mar 11, 2026
StartActual
Feb 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07464106
Lead sponsor
Robert Bosch Medical Center
Responsible party
Moritz Schanz (MD, PD Dr., Robert Bosch Medical Center) — Principal investigator
First posted
Mar 11, 2026
Start date
Feb 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 11, 2026

Study contacts

Andrea Schwab
Contact
Sekretariat-Nephrologie@rbk.de
071181010

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion